 Shares of Bicycle Therapeutics Inc. BCYC, 24.54 tumbled 23.4 in premarket trading on Monday after the company shared interim data from a Phase 1 clinical trial for its urothelial-cancer treatment. Bicycle said its experimental therapy, BT8009, had a 50 overall response rate, and one of the eight patients enrolled in the study who received the smallest dose of the therapy reported a complete response. 